Peptide vaccine trial for head and neck cancer halted early
NCT ID NCT04445064
First seen Jan 11, 2026 · Last updated May 03, 2026 · Updated 13 times
Summary
This study tested a peptide-based immunotherapy given before surgery in 17 people with head and neck cancer. The goal was to see if the vaccine could activate the immune system against the tumor and to check for side effects. The trial was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARYNX SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cliniques Universitaires Saint-Luc
Brussels, 1200, Belgium
Conditions
Explore the condition pages connected to this study.